Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553875 | 1.00 | CYP19A1 (0.50) | CYP19A1HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL9180325 | 1.00 | CYP19A1 (0.50) | CYP19A1HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL11138250 | 0.91 | MAPT (0.46) | CYP19A1HPGDALDH1A1KDM4EGAA | |
| SCHEMBL11138252 | 0.91 | MAPT (0.46) | CYP19A1HPGDALDH1A1KDM4EGAA | |
| SCHEMBL76803 | 0.88 | HPGD (0.43) | CYP19A1HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL76804 | 0.88 | HPGD (0.43) | CYP19A1HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL1554070 | 0.87 | DHODH (0.44) | CYP19A1HPGDALDH1A1KDM4EGAA | |
| SCHEMBL1554071 | 0.87 | DHODH (0.44) | CYP19A1HPGDALDH1A1KDM4EGAA | |
| SCHEMBL77911 | 0.85 | HPGD (0.50) | HPGDMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL77912 | 0.85 | HPGD (0.50) | HPGDMAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308642-A1 | STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-01-24 | — | — | EP | disclosed |
| EP-4214275-A1 | USE OF DIEUGENOL, OLIGOMERS AND/OR POLYMERS OF EUGENOL FOR STABILIZING ORGANIC MATERIALS, STABILIZED PLASTICS COMPOSITION, STABILIZER COMPOSITION AND METHOD FOR STABILIZING ORGANIC MATERIALS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-07-26 | — | — | EP | disclosed |
| EP-4139385-A1 | USE OF INORGANIC SULPHITES AND/OR THIOSULPHATES FOR STABILISING ALIPHATIC POLYESTERS, STABILISED MOULDING COMPOSITIONS AND MOULDING COMPOSITIONS AND MOULDED PARTS PRODUCED THEREFROM | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022195041-A1 | STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022058371-A1 | USE OF DIEUGENOL, OLIGOMERS AND/OR POLYMERS OF EUGENOL FOR STABILIZING ORGANIC MATERIALS, STABILIZED PLASTICS COMPOSITION, STABILIZER COMPOSITION AND METHOD FOR STABILIZING ORGANIC MATERIALS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021213940-A1 | USE OF INORGANIC SULPHITES AND/OR THIOSULPHATES FOR STABILISING ALIPHATIC POLYESTERS, STABILISED MOULDING COMPOSITIONS AND MOULDING COMPOSITIONS AND MOULDED PARTS PRODUCED THEREFROM | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-10-28 | — | — | WO | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1383463-B1 | FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN | KING PHARMACEUTICALS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1383463-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7101905-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-08-17 | — | — | US | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-1383463-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | King Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002083083-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-5473003-A | A styrene copolymer blend comprising a stabilizer for heat, oxidation, chemical and actinic radiation resistance | CIBA-GEIGY CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0336606-A1 | Composition of stabilized synthetic resin | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | CYP19A1 3845/4885HPGD 726/4885HDAC3 1473/4885 |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | CYP19A1 3845/4885HPGD 726/4885HDAC3 1473/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | CYP19A1 512/4885HPGD 1231/4885HDAC3 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.